Kala Bio (KALA) Total Debt (2016 - 2025)
Kala Bio (KALA) posted Total Debt of $28.4 million for Q3 2025, little changed sequentially from $28.3 million in Q2 2025, and down 19.15% YoY from $35.1 million in Q3 2024.
Kala Bio (KALA) Total Debt (2016 - 2025) Analysis & Trends
Kala Bio has reported Total Debt for 10 years, with the latest figure at $28.4 million in Q3 2025.
- Quarterly Total Debt fell 19.15% year-over-year to $28.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.4 million (down 19.15% YoY) and the FY2024 annual result came in at $30.4 million, down 10.97% from the prior year.
- Total Debt steadied at $28.4 million in Q3 2025 per KALA's latest filing, from $28.3 million in the prior quarter.
- Over five years, Total Debt peaked at $83.6 million in Q2 2022 and troughed at $28.3 million in Q2 2025.
- A 5-year average of $48.6 million and a median of $34.8 million in 2024 frame the typical range for Total Debt.
- The sharpest annual moves came in 2021 and 2023: Total Debt advanced 14.54% in 2021, then tumbled 59.93% in 2023.
- Over 5 years, Total Debt stood at $82.7 million in 2021, then slumped by 49.14% to $42.1 million in 2022, then fell by 18.76% to $34.2 million in 2023, then slipped by 10.97% to $30.4 million in 2024, then slipped by 6.66% to $28.4 million in 2025.
- According to Business Quant data, Total Debt over the past three periods registered $28.4 million, $28.3 million, and $30.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 28.41 Mn |
| Jun 30, 2025 | 28.30 Mn |
| Mar 31, 2025 | 30.62 Mn |
| Dec 31, 2024 | 30.44 Mn |
| Sep 30, 2024 | 35.14 Mn |
| Jun 30, 2024 | 34.82 Mn |
| Mar 31, 2024 | 34.50 Mn |
| Dec 31, 2023 | 34.19 Mn |
| Sep 30, 2023 | 33.88 Mn |
| Jun 30, 2023 | 33.57 Mn |
| Mar 31, 2023 | 33.27 Mn |
| Dec 31, 2022 | 42.08 Mn |
| Sep 30, 2022 | 46.57 Mn |
| Jun 30, 2022 | 83.57 Mn |
| Mar 31, 2022 | 83.03 Mn |
| Dec 31, 2021 | 82.75 Mn |
| Sep 30, 2021 | 78.49 Mn |
| Jun 30, 2021 | 78.06 Mn |
| Mar 31, 2021 | 72.52 Mn |
| Dec 31, 2020 | 72.24 Mn |